SinoBioData Academic Portal
ZW
Verified CAS / Academic Author2 Decoded Studies

Prof. ZOU Weiwei

Jiangxi University of Chinese Medicine, Nanchang 330004, China; National Pharmaceutical Engineering Research Center for Solid Preparation in Chinese Herbal Medicine, Nanchang 330006, China

Co-Affiliations:Southern Medical University

Research Publications & English Decoded Briefs

Showing 2 publications
Chinese Traditional and Herbal Drugs2026DOI: 10.7501/j.issn.0253-2670.2026.16.20261629

Advances in the Application of Single-Cell Transcriptomics to Studies of Arthritis Pathogenesis and Treatment with Traditional Chinese Medicine

Arthritis incidence has risen steadily, with complex and protracted pathological progression; it remains among the leading causes of disability worldwide. Existing therapeutic approaches, including traditional Chinese medicine (TCM) hot compress and acupuncture, provide symptomatic relief but rarely achieve disease modification, and some carry adverse effects. TCM's multi-component, multi-target, multi-pathway characteristics are mechanistically compatible with arthritis heterogeneity, yet its pharmacodynamic basis remains poorly resolved at the cellular level. Bulk RNA sequencing averages transcriptional signals across cell populations, obscuring rare pathogenic subpopulations and cell-state transitions. Single-cell RNA sequencing (scRNA-seq) resolves gene expression heterogeneity at single-cell resolution, enabling construction of joint tissue cellular atlases and identification of key subpopulations and molecular targets driving disease progression. This review systematically summarizes the technical advantages of scRNA-seq relative to bulk RNA-seq, including platforms such as 10× Genomics and BD, and examines its application to rheumatoid arthritis, osteoarthritis, and gouty arthritis. It further discusses prospects and challenges for integrating scRNA-seq into TCM-based arthritis research, including cell-cell communication inference, macrophage M1/M2 polarization analysis, and SPP1+ chondrocyte identification, providing a reference for mechanistic studies and development of novel Chinese herbal therapeutics.

Stem Cell Research & Therapy2026DOI: 10.1186/s13287-026-05100-7

A noncanonical neuroligin 3-centered complex promotes functional recovery of spinal cord injury

Background: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) hold therapeutic potential for spinal cord injury (SCI), yet their mechanisms remain unclear. We hypothesized that investigating in situ transcriptional reprogramming of transplanted hUC-MSCs within the spinal cord microenvironment (SCE) could identify crucial genes for SCI repair. Methods: DiD-labeled hUC-MSCs were intrathecally transplanted in rats with or without sub-acute spinal cord bilateral hemisection injury and retrieved for RNA-seq. Comparative transcriptomic analysis and functional screenings in vitro and in vivo, including heterologous synapse formation assay, transplantation of MSCs with gene overexpression or knockdown, AAV-mediated neuron-specific gene expression in SCI rats, behavioral tests, and motor evoked potentials (MEPs), identified Neuroligin 3 (Nlgn3) as a novel target. Immunoprecipitation-mass spectrometry (IP-Mass spec), cell aggregation assay, and immuno-electron microscopy revealed functional interacting partners. RT-qPCR, western blotting, immunofluorescence, and co-IP elucidated mechanisms. Results: NLGN3, a neuronal cell adhesion molecule activated by SCE in transplanted hUC-MSCs, promoted therapeutic efficacy. Neuron-specific restoration of Nlgn3 in injured spinal cord alone achieved comparable therapeutic effects. Mechanistically, Nlgn3 recruits synaptic vesicle proteins Sar1a and Hspa8 to modulate synaptic strength. Combinatorial restoration of Nlgn3 with Sar1a or Hspa8 synergistically enhanced SCI repair. Conclusions: This work unveils a novel therapeutic role for Nlgn3 in SCI, enhancing MSC transplantation efficacy and directly promoting neural circuit reconstruction.